Conmed’s 2.2 percent convertible notes are funding the transaction, according to a June 13 news release. In2Bones’ portfolio includes implants, fracture systems and biologic products.
The deal was announced in May. The acquisition includes up to an additional $110 million in growth-based earnout payments over four years.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
